文献速递胸部肿瘤

NEPTUNE:度伐利尤单抗联合替西木单抗一线治疗转移性非小细胞肺癌的3期研究

NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC.
PubMed 文献 · J Thorac Oncol · 2022-10-12

NEPTUNE是一项3期开放标签研究,评估度伐利尤单抗联合替西木单抗对比化疗一线治疗EGFR/ALK野生型转移性非小细胞肺癌。研究未达到主要终点:在bTMB≥20 mut/Mb患者中,联合组对比化疗的总生存改善未达统计学显著(HR 0.71,95%CI 0.49-1.05,P=0.081;中位OS 11.7 vs 9.1个月)。

要点

  • 主要终点未达到:bTMB≥20 mut/Mb患者中联合组对比化疗的OS改善无统计学显著性。
  • bTMB≥20 mut/Mb患者中,联合组中位PFS 4.2个月 vs 化疗组5.1个月(HR 0.77,95%CI 0.51-1.15)。
  • 总体安全性人群中,联合组3/4级治疗相关不良事件发生率为20.7%,化疗组为33.6%。

核心结论

  • NEPTUNE研究未达到主要终点,即在bTMB≥20 mut/Mb的转移性NSCLC患者中,度伐利尤单抗联合替西木单抗对比化疗未能显著改善OS。
  • 尽管研究设计经修订导致主要分析人群较小,但治疗活性与基于机制生物学和既往研究的预期一致。

研究设计与样本

  • NEPTUNE是一项3期、开放标签研究,评估度伐利尤单抗联合替西木单抗对比标准化疗一线治疗EGFR和ALK野生型转移性非小细胞肺癌(mNSCLC)。
  • 符合条件的患者按1:1随机分配至度伐利尤单抗(20 mg/kg,每4周一次,直至疾病进展)联合替西木单抗(1 mg/kg,每4周一次,最多4剂)组或标准化疗组。
  • 随机化按肿瘤PD-L1表达(≥25% vs <25%)、肿瘤组织学类型和吸烟史分层。
  • 修订后的主要终点为bTMB≥20 mut/Mb患者的总生存期(OS)。
  • 截至2019年6月24日,共823例患者随机分配(意向治疗人群);512例(62%)可评估bTMB,其中129/512例(25%)bTMB≥20 mut/Mb(联合组n=69;化疗组n=60)。

主要发现

  • 在bTMB≥20 mut/Mb患者中,联合组对比化疗组的OS改善未达统计学显著(HR 0.71,95%CI 0.49-1.05,P=0.081;中位OS 11.7个月 vs 9.1个月)。
  • 在bTMB≥20 mut/Mb患者中,联合组对比化疗组的PFS HR为0.77(95%CI 0.51-1.15;中位PFS 4.2个月 vs 5.1个月)。
  • 在总体安全性人群中,联合组3级或4级治疗相关不良事件发生率为20.7%,化疗组为33.6%。

关键数值与推荐

  • bTMB≥20 mut/Mb患者中,联合组中位OS为11.7个月,化疗组为9.1个月(HR 0.71,95%CI 0.49-1.05,P=0.081)。
  • bTMB≥20 mut/Mb患者中,联合组中位PFS为4.2个月,化疗组为5.1个月(HR 0.77,95%CI 0.51-1.15)。
  • 总体安全性人群中,联合组3/4级治疗相关不良事件发生率为20.7%,化疗组为33.6%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 研究设计经修订,导致主要分析人群较小。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: NEPTUNE, a phase 3, open-label study, evaluated first-line durvalumab plus tremelimumab versus chemotherapy in metastatic NSCLC (mNSCLC). METHODS: Eligible patients with EGFR and ALK wild-type mNSCLC were randomized (1:1) to first-line durvalumab (20 mg/kg every 4 weeks until progression) plus tremelimumab (1 mg/kg every 4 weeks for up to four doses) or standard chemotherapy. Randomization was stratified by tumor programmed death-ligand 1 expression (≥25% versus <25%), tumor histologic type, and smoking history. The amended primary end point was overall survival (OS) in patients with blood tumor mutational burden (bTMB) greater than or equal to 20 mutations per megabase (mut/Mb). Secondary end points included progression-free survival (PFS) in patients with bTMB greater than or equal to 20 mut/Mb and safety and tolerability in all treated patients. RESULTS: As of June 24, 2019, 823 patients were randomized (intention-to-treat [ITT]); 512 (62%) were bTMB-evaluable, with 129 of 512 (25%) having bTMB greater than or equal to 20 mut/Mb (durvalumab plus tremelimumab [n = 69]; chemotherapy [n = 60]). Baseline characteristics were balanced in the intention-to-treat. Among patients with bTMB greater than or equal to 20 mut/Mb, OS improvement with durvalumab plus tremelimumab versus chemotherapy did not reach statistical significance (hazard ratio 0.71 [95% confidence interval: 0.49-1.05; p = 0.081]; median OS, 11.7 versus 9.1 months); the hazard ratio for PFS was 0.77 (95% confidence interval, 0.51-1.15; median PFS, 4.2 versus 5.1 months). In the overall safety population, incidence of grade 3 or 4 treatment-related adverse events was 20.7% (durvalumab plus tremelimumab) and 33.6% (chemotherapy). CONCLUSIONS: NEPTUNE did not meet its primary end point of improved OS with durvalumab plus tremelimumab versus chemotherapy in patients with mNSCLC and bTMB greater than or equal to 20 mut/Mb. Despite the amended study design, with a resultant small primary analysis population, therapeutic activity was aligned with expectations based on mechanistic biology and previous studies.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. de Castro G, Rizvi NA, Schmid P, et al. NEPTUNE: Phase 3 Study of First-Line Durvalumab Plus Tremelimumab in Patients With Metastatic NSCLC. J Thorac Oncol. 2022. PMID: 36240972. doi:10.1016/j.jtho.2022.09.223

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。